Tag: Cherries

Due to its potential to improve cognitive function, the chemical molecule dimethylaminoethanol (DMAE), commonly known as deanol, has attracted attention lately. The neurotransmitter acetylcholine,...

The acai (Euterpe oleracea) fruit is endemic to Central and South America, primarily in the Amazon jungle. Acai has grown in popularity as a...

Memory loss, particularly from dementia and Alzheimer's disease, is a growing concern worldwide. It affects millions of individuals and their families, posing significant challenges to healthcare systems. Historically, treatment options have been limited. They often focus on managing symptoms rather than addressing the underlying disease processes. However, the landscape of memory loss treatment is changing. Recent breakthroughs in medication are offering new hope for patients and their families. One such breakthrough is donanemab, a new medication that targets the amyloid-beta plaques associated with Alzheimer's disease. Its potential effectiveness in slowing cognitive decline has sparked significant interest in the medical community. This article will delve into the details of these new medications, their mechanisms of action, and their potential impact on patients' lives. We'll compare donanemab with donepezil, a commonly prescribed Alzheimer's medication, and discuss the implications of the FDA's accelerated approval of new Alzheimer's drugs.

Mild Cognitive Impairment, or MCI, is a condition characterized by cognitive changes that are more significant than those expected from normal aging but not severe enough to interfere significantly with daily life or independent function. MCI is a middle ground between normal age-related cognitive decline and more severe dementia.